Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19

 Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19

Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19

Shots:

  • The ongoing P-III trial involves assessing REGEN-COV (casirivimab & imdevimab) in 2000+ participants used as a passive vaccine to prevent COVID-19. An exploratory analysis, conducted on the first ~400 individuals, randomized to receive passive vaccination with REGEN-COV (1200mg, SC) vs PBO
  • Reduction in overall infections seen within 1st week with 100% prevention of symptomatic infections, 50% lower overall rates of infection and decreased peak virus levels and duration of viral shedding in asymptomatic infections
  • The confirmatory P-III results are expected early in Q2’21. REGEN-COV is being studied in two hospitalized patient trials and a P-III study for non-hospitalized patients

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: CNBC

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post